All stocks
ALNYIndustry: Biotechnology
Alnylam Pharmaceuticals, Inc.
$227.94
+1.8%
52-week range
$197.81$485.36
- Market cap
- $30 bn
- P/E
- 37.1
- EPS (TTM)
- $5.88
- Beta
- 0.38
- Dividend yield
- —
- 1-year change
- -51.7%
- 3 months
- -17.6%
- Revenue growth (YoY)
- +95.1%
- Net margin
- 16.8%
Share price since 2016
Monthly closing prices adjusted for stock splits.
Earnings per share: estimate vs actual
Beat estimates in 2 of the last 4 reports
2.11
Q3 25
0.82
Q4 25
1.51
Q1 26
1.21
Q2 26
1.65
Q3 26
EstimateActual
| Quarter | EPS | Surprise | Revenue | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.21 / $1.59 | -23.7% | — | — |
| Q1 2026 | $1.51 / $0.98 | +53.8% | — | — |
| Q4 2025 | $0.82 / $1.15 | -28.5% | — | — |
| Q3 2025 | $2.11 / $0.76 | +177.2% | — | — |
Data updated: October 26, 2026 at 05:12 PM UTC Prices are as of the data update, not real time. Live quotes are in the terminal.